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Structure-Guided Design of Sialic Acid-Based
Siglec Inhibitors and Crystallographic Analysis
in Complex with Sialoadhesin
providing further ideas for compound design of physi-
ological and potentially therapeutic relevance.
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Division of Structural Biology The sialic acid binding immunoglobulin (Ig)-like lectins
(Siglecs) comprise a family of some 11 type 1 membraneThe Henry Wellcome Building for Genomic Medicine
Roosevelt Drive receptors [1, 2]. Family members have a differential ex-
pression pattern but are mainly found on cells of theHeadington
Oxford OX3 7BN hematopoietic system. They are characterized by their
recognition of sialylated glycoconjugates through spe-United Kingdom
2 Oxford Centre for Molecular Sciences cific binding of the oligosaccharide’s N-acetylneur-
aminic acid (Neu5Ac) portion to the N-terminal Ig-likeNew Chemistry Building
South Parks Road domain of their extracellular region.
Sialic acids are a family of over 40 derivatives ofOxford OX1 3QT
United Kingdom N-acetylneuraminic acid (Neu5Ac). As mainly terminal
components of glycans on glycoproteins and glycolip-3 Wellcome Trust Biocentre
School of Life Sciences ids, they contribute to the structural variability of the
cell surface glycocalix. This is further enhanced by theUniversity of Dundee
Dundee DD1 5EH different modifications, which are cell-type specific and
developmentally controlled. Because of their exposedScotland
4 Biochemistry Center Heidelberg position, Neu5Ac derivatives are involved in numerous
cellular recognition processes, such as pathogen adhe-University of Heidelberg
69120 Heidelberg sion and cellular interactions [3–5].
The biological functions and mechanisms of action ofGermany
5 Centre for Biomolecular Interactions Bremen the Siglecs are an area of active research. Several con-
tain immunoreceptor tyrosine-based inhibition motifsDepartment of Biology and Chemistry
University Bremen (ITIMs) in their cytoplasmic tails. These include CD22
(Siglec-2), an inhibitory receptor of B cells, CD33Leobener Str. NW2
28359 Bremen (Siglec-3), and seven recently identified CD33-related
Siglecs, for example, Siglec-7, a putative NK cell inhibi-Germany
tory receptor (reviewed by Crocker and Varki [1]). In
contrast, myelin-associated glycoprotein (MAG; Siglec-
4) lacks an ITIM motif and is expressed on myelinating
cells of the nervous system, oligodendrocytes, andSummary
Schwann cells and appears to play an important role in
the maintenance of myelin-axon integrity [6–8]. MAGThe Siglec family of receptors mediates cell surface
interactions through recognition of sialylated glyco- occurs in two splice variants. One of these, L-MAG,
contains a tyrosine phosphorylation site different fromconjugates. The crystal structure of the N-terminal
immunoglobulin-like domain of the Siglec siaload- the ITIM motifs of most other Siglecs [9]. An interesting
feature of MAG is its inhibitory activity on neurite out-hesin (SnD1) in complex with 2,3-sialyllactose has in-
formed the design of sialic acid analogs (sialosides) growth [10–12].
While all Siglecs, by definition, recognize Neu5Ac,that bind Siglecs with significantly enhanced affinities
and specificities. Binding assays against sialoadhesin they show considerable variation in their specificity for
different glycosidic linkages. All except for Siglec-6,(Sn; Siglec-1), CD22 (Siglec-2), and MAG (Siglec-4)
however, recognize forms and linkages of sialic acid thatshow a 10- to 300-fold reduction in IC50 values (relative
are common on mammalian extracellular glycoproteinsto methyl--Neu5Ac) for three sialosides bearing aro-
and glycolipids. For example, CD22 strongly prefersmatic group modifications of the glycerol side chain:
2,6-linked sialic acids [13–15], MAG prefers 2,3-linkedMe--9-N-benzoyl-amino-9-deoxy-Neu5Ac (BENZ),
sialic acid [14], and Siglec-7 shows a clear preference forMe--9-N-(naphthyl-2-carbonyl)-amino-9-deoxy-
2,8-linked disialic acids [16]. Siglec-sialic acid bindingNeu5Ac (NAP), and Me--9-N-(biphenyl-4-carbonyl)-
events thus appear well suited to mediating selectiveamino-9-deoxy-Neu5Ac (BIP). Crystal structures of
cell surface interactions, and, for a number of the Sig-these sialosides in complex with SnD1 suggest expla-
lecs, it has been proposed that such interactions playnations for the differences in specificity and affinity,
a role in the regulation of the innate immune system [1].
Sialoadhesin (Sn; Siglec-1) is the prototypic Siglec
*Correspondence: yvonne.jones@strubi.ox.ac.uk
6 Present address: Medical Institute of Bioregulation, Kyushu Univer- Key words: Siglecs; inhibitor design; sialic acid binding; crystal
structure; lectins; sialoadhesinsity 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Structure
558
Table 1. Comparison of Inhibitory Potentials of Sialosides to Different Siglecs
rIP
mSn hCD22 mCD22 MAG
methyl--Neu5Ac 1 1 1 1
BENZ 2.1 4.8 4.3 790
NAP 11 110 17 270
BIP 13 224 5 250
methyl--9-N-biphenyl-4-acetyl-deoxy-amino-Neu5Ac 0.3 29 48 ND
methyl--9-N-acetyl-9-deoxy-9-amino-Neu5Ac 0.2 0.6 2.7 2.1
methyl--9-deoxy-Neu5Ac No inhibition No inhibition No inhibition No inhibition
The relative inhibitory potencies (rIPs) of each sialoside were determined against methyl--Neu5Ac. They were calculated by dividing the IC50
value of the indicated reference compound (methyl--Neu5Ac) by the IC50 value of the compound of interest. This results in rIPs above 1.0
for inhibitors that inhibit better than the reference compound and rIPs lower than 1.0 for sialosides that inhibit more weakly than the reference
compound. ND, not determined.
and is expressed on subsets of macrophages [17]. Al- alosides to Sn. When combined with sequence analysis
and modeling, the sialoside-SnD1 complexes also sug-though the extracellular region contains 17 Ig-like do-
mains, the N-terminal domain (SnD1) alone is fully com- gest putative structural features responsible for the ob-
served specificities of the sialosides when binding topetent to mediate sialic acid binding [18]. The crystal
structure of SnD1 (expressed as a soluble molecule) has MAG and CD22.
been reported in complex with the sialic acid conjugate
2,3-sialyllactose [19]. This structure revealed the struc- Results
tural template for sialic acid recognition by the Siglecs.
The 2,3-sialyllactose binding is almost entirely mediated Compounds Studied and Siglec Binding Data
A novel approach to the preparation of analogs substi-through interactions with the Neu5Ac, and the structural
features involved are predicted to be present in all Sig- tuted at C-9 of Neu5Ac (methyl--Neu5Ac) was devel-
oped with a Mitsunobu reaction-based synthesis. Thelecs. These include interactions with three sialoadhesin
residues (Trp2, Arg97, and Trp106) that constitute a common scaffold for these compounds retains the
methyl--Neu5Ac structure up to the terminal hydroxylNeu5Ac binding motif conserved in all Siglec domain 1
sequences [19, 20]. Mutagenesis of these residues and group of the standard glycerol side chain, at which point
the O-9 is substituted by an amido nitrogen as part oftheir equivalents in other Siglecs abolishes or greatly
reduces sialic acid binding [19, 21, 22]. a peptide linkage to an additional substituent group.
On the basis of inspection of the 2,3-sialyllactose/SnD1The binding affinities of Siglecs to sialic acid typify
the relatively low values reported for monovalent cell structure in the interactive graphics program O [29], a
range of aliphatic and aromatic substituent groups weresurface receptor-carbohydrate interactions (e.g., for the
selectins; [23]). For example, the binding affinity of sialo- selected. The resultant sialosides were tested in hapten
inhibition assays against a panel of three Siglecs: Sn,adhesin to the minimal sialic acid moiety, methyl-
-Neu5Ac, is in the 1–3 mM range [24, 25]. There is also MAG, and CD22 ([28]; our unpublished data). Binding
data for a representative subset of these compoundslittle difference in the binding affinities of this single
sugar ring compound to several Siglecs (our unpub- are reproduced in Table 1. Three of the sialosides con-
taining aromatic ring substituents showed particularlylished data). This common binding affinity is in line with
the predicted conservation in all Siglecs of the structural interesting binding characteristics. They are Me--9-
N-benzoyl-amino-9-deoxy-Neu5Ac (BENZ), Me--9-N-features mediating interactions with Neu5Ac. Inspection
of the 2,3-sialyllactose/SnD1 structure, however, sug- (napthyl-2-carbonyl)-amino-9-deoxy-Neu5Ac (NAP), and
Me--9-N-(biphenyl-4-carbonyl)-amino-9-deoxy-Neu5Acgested that sialic acid analogs in the -glycosidic form
(sialosides) with modified substituents in the glycerol (BIP) (R.B. and S. Geis, in preparation). The chemical
structures of these compounds are detailed in Figureside chain could yield increased binding affinities ([26–
28]; our unpublished data). Equally importantly, se- 1. BENZ shows a strong and specific enhancement in
binding to MAG. The addition of a second aromatic ringquence comparison of Sn and the other Siglecs indi-
cated that such compounds would be likely to display structure in NAP results in some reduction in binding
affinity to MAG, but significantly increased affinity to Snenhanced specificity to individual family members. Such
reagents could potentially aid in the dissection of Siglec and CD22. Finally, aligning the two aromatic rings in the
BIP compound results in only a slight increase in bindingfunction [28].
We report here sialoside-SnD1 crystal structures for affinity to Sn, but, most notably, a high affinity for human
CD22 (rIP of 224 against Neu5Ac; IC50  4 M).three sialosides bearing modified glycerol substituents.
These sialosides have been shown to have enhanced
affinities and specificities in binding assays to three Crystal Structures of the Sialoside-SnD1 Complexes
Structure of the Bound Inhibitors and ConservedSiglecs (MAG, Sn, and CD22) and have been used for
functional studies on CD22 [28]. The crystal structures Sialoside-SnD1 Interactions
The crystal structures of SnD1 in complex with BENZ,indicate the structural elements and interactions re-
sponsible for the differences in the affinity of these si- NAP, and BIP were determined by molecular replace-
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Figure 1. Chemical Structures of Sialosides
Used in This Study
ment (see Experimental Procedures). Despite similar from  strand G as well as with the side chains of resi-
dues Trp2 and Arg97. All of the interactions made bycrystallization conditions to those of the SnD1-2,3-sialyl-
lactose complex [19], the current three complexes crys- the Neu5Ac in the SnD1-2,3-sialyllactose complex can
be duplicated exactly in the current SnD1-sialosidetallized in a different space group (P43212 compared with
P212121 for SnD1-2,3-sialyllactose). This change proba- complexes except for the hydrogen bond between the
hydroxyl group at C-9 of the glycerol side chain andbly results from the involvement of the glucose of the
2,3-sialyllactose in crystal packing contacts. The struc- the main chain carbonyl of Leu107. In BENZ, NAP, and
BIP, the nitrogen of the amide linkage is substituted fortures of SnD1-BENZ, SnD1-NAP, and SnD1-BIP, plus
that of SnD1-2,3-sialyllactose, are shown in Figures 2 the O-9, and, as planned in the design of these com-
pounds, the complex structures reveal that this posi-and 3. Hydrogen bonds between SnD1 and the different
bound sialic acid analogs are detailed in Table 2. tion’s hydrogen bonding capability to the Leu107 car-
bonyl is maintained.The positions of atoms common to two or more of
the bound compounds (including 2,3-sialyllactose) are The glycerol side chain substituents were designed to
exploit the potential for an auxiliary binding site directlyconserved in the complexes. For the BENZ, NAP, and
BIP sialosides, when unliganded in solution, several bordering on the Neu5Ac binding site in the 9 direction.
In Sn this putative binding site comprises a cluster ofpossible angular conformations may be expected to ex-
ist around the bond between the amino group and the hydrophobic residues (Tyr44, Leu107, and Val109).
While the structure of the Neu5Ac binding site is pre-first aromatic ring. In complex with SnD1 the aromatic
extensions in the 9 direction of the sialosides are all dicted to be highly conserved throughout the Siglec
family, sequence analysis implies some variation in thisoriented in the same plane and are well ordered.
As expected, Neu5Ac, common to each of the com- peripheral region. Thus, additional sialoside interactions
at this site could potentially confer Siglec specificity aspounds, has a conserved interaction mode with Sn in
all of the complexes. As reported by May and coworkers well as increased affinity, effects indeed achieved for
the BENZ, NAP, and BIP compounds.[19], this involves interactions with main chain atoms
Figure 2. The Neu5Ac Binding Site and Structures of the Bound Sialosides
(A) A ribbon representation of Neu5Ac/protein interactions in the 2,3-sialyllactose-Snd1 structure. Key residues are shown in ball and stick
(red, oxygen; blue, nitrogen; black, protein carbon; yellow, sugar carbon).
(B–D) Three-dimensional structures of the BENZ, NAP, and BIP compounds (ball and stick representation color-coded as in [A]). Fo  Fc omit
map electron density (blue mesh; contoured at 3 ) was calculated after simulated annealing with the sialoside (plus any residue within a
distance of 3.5 A˚) omitted.
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Table 2. Hydrogen Bonds between Snd1 and Bound Ligand
Atom in Sialic Acid 2,3-Sialyllactose-SnD1 Complex BEN-SnD1 Complex NAP-SnD1 Complex BIP-SnD1 Complex
Amine-5 2.8 A˚ 2.7 A˚ 3.0 A˚ 2.8 A˚
Carbonyl 105 Carbonyl 105 Carbonyl 105 Carbonyl 105
Carbonyl-5 — — — —
O1A 3.1 A˚ 2.9 A˚ 3.2 A˚ 3.3 A˚
NH1 Arg97 NH1 Arg97 NH1 Arg97 NH1 Arg97
O1B 3.1 A˚ 2.9 A˚ 3.0 A˚ 3.7 A˚
NH1 Arg97 NH1 Arg97 NH1 Arg97 NH1 Arg97
Hydroxyl-4 2.8 A˚ 2.6 A˚ 2.5 A˚ 2.7 A˚
Carbonyl 103 Carbonyl 103 Carbonyl 103 Carbonyl 103
Pyranose-oxygen — — — —
Hydroxyl-7 — — — —
Hydroxyl-8 2.8 A˚ 2.9 A˚ 3.1 A˚ 2.9 A˚
Amine 107 Amine 107 Amine 107 Amine 107
Hydroxyl-9 2.7 A˚ NA NA NA
Carbonyl 107
Amine-9 NA 3.1 A˚ 3.2 A˚ 2.9 A˚
Carbonyl 107 Carbonyl 107 Carbonyl 107
Potential hydrogen bond donors and acceptors of each sialoside to Snd1 are detailed. NA, not applicable.
BENZ/SnD1 Interactions and the SnD1-2,3-sialyllactose complexes (root-mean-
square deviation of 0.4 A˚ for C atoms and 0.9 A˚ for allThe phenyl ring of the BENZ compound interacts with
the hydrophobic side chains of Tyr44, Leu107, and protein atoms). Of the three residues directly abutting
the phenyl binding site, the conformation of one, Leu107,Val109. Comparison with the SnD1-2,3-sialyllactose
structure reveals that four tightly bound water molecules is unaltered. The other two residues provide the two
structural rearrangements of the protein’s surface, con-are displaced as a result (Figure 3). In general, the protein
structure is highly conserved between the SnD1-BENZ sequent on BENZ binding. Val109 is displaced by a rota-
Figure 3. Details of the Snd1-Sialoside Com-
plex Structures
(A–D) Close-up view of Me-Neu5Ac/protein
interaction in the 2,3-sialyllactose-Snd1
structure of the BENZ-Snd1, NAP-Snd1, and
BIP-Snd1 complexes. Side chains involved in
the interaction with the sialoside’s aromatic
rings are depicted. Water molecules are rep-
resented as red spheres. Note the difference
in conformation of Tyr44 and Ser45 between
the different complexes.
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tion of its side chain, in order to create a channel through substitution of the single phenyl ring of BENZ with the
rigidly fused pair of rings of the naphthyl group (NAP)which the inhibitor can slot. The side chain of Tyr44
also shows some propensity to rotate around its C-C adds no additional degrees of conformational freedom
to the sialoside, and the ratio of binding energies tobond, bringing its ring into partial van der Waals contact
with the phenyl group of the BENZ. This altered confor- difference in buried surface for NAP and BENZ binding
(0.029 kcal/mol/A˚2 ) duly lies within the range reportedmation is, however, not strongly favored and is only
observed at about 50% occupancy. by several other groups (0.024 to 0.120 kcal/mol/A˚2 )
[30–33]. This is not the case on comparison of BIP andNAP/SnD1 Interactions
The structure of the NAP sialoside is identical to that of NAP binding. Although the more extended arrangement
of the two rings in the BIP substituent does somewhatBENZ except for the addition of a second aromatic ring
(Figure 1). Structural comparison reveals that these further increase the buried surface, this relatively small
gain is in large part cancelled out by the entropic penaltycommon structural elements are found in essentially
identical positions in both Sn-sialoside complexes, and, arising from the loss of rotational freedom between the
two rings (an estimated 0.260 kcal/mol per rotatabletherefore, the interactions between the NAP compound
and SnD1 are very similar to the interactions previously bond [30]).
Several sialic acid analogs, modified in the 9 direc-described for the SnD1-BENZ complex (Figure 3 and
Table 2). The extra aromatic ring of NAP provides some tion, have been reported to have low affinities to Sn
and other Siglecs. Methyl-9-N-(3,5-dinitrobenzoyl)-additional van der Waals interactions with residues
Ser45 and Asn95. Residue Val109 is displaced in a simi- amino Neu5Ac is closely related to BENZ but shows
reduced affinity to Sn (rIP  0.3, relative to Me-lar manner to that observed in the BENZ-SnD1 structure.
The position and conformation of the Tyr44 residue is -Neu5Ac). Model building based on the BENZ-SnD1
complex reveals that this loss of affinity may be ex-identical to the one observed in the SnD1-2,3-sialyllac-
tose complex, as the longer naphthalene group sterically plained by steric clashes of one of the nitro groups with
the side chain of Leu107 and the main chain atoms ofhinders the reorientation of the tyrosine side chain ob-
served at partial occupancy in the SnD1-BENZ complex. Asp108. Similarly, the BIP-related compound biphenyl-
4-acetyl-amino Neu5Ac exhibited low affinity to siaload-BIP/SnD1 Interactions
No major differences are observed between the protein hesin (rIP  0.3, relative to Me--Neu5Ac) (Table 1).
Examination of the BIP-SnD1 structure indicates thatstructure in the SnD1-BIP complex and that of the NAP-
SnD1 complex. In particular, Tyr44 and Val109 are found the lengthening of the sialoside by the extra methylene
would result in a steric clash with Ser45. Finally, the lackin the same orientations. Equivalent atoms between
these two sialoside compounds occupy similar posi- of binding to CD22 and Sn of 9-O-acetyl-Neu5Ac (data
reported prior to any Sn crystal structure) [15, 34, 35] andtions. The two phenyl rings of the bound BIP are oriented
in the same direction and are at solvent-excluding dis- to 9-deoxy-Neu5Ac [25] underscores the importance of
conserving the hydrogen bond to the carbonyl of Leu107tances from the Tyr44, Ser45, and Asn95 side chains.
The only residue showing a conformational change in a mediated by the OH-9 in the standard glycerol side
chain. Clearly the current complexes can inform furthercomparison with the SnD1-NAP structure is Ser45; the
side chain has rotated in order to reduce the solvent sialoside design to incorporate additional hydrogen
bond interactions.exposure of the sialoside’s hydrophobic rings.
Discussion Implications of the Binding Affinities
to Other Siglecs
CD22Structure-Based Interpretation of Sialoside
Binding Affinities to Sn The BIP compound exhibited a much higher affinity to
human CD22 (hCD22) (rIP  224, relative to Me-The observed binding affinities of the sialosides to Sn
reported in Table 1 may now be rationalized in the con- -Neu5Ac) than to Sn (rIP  13) (Table 1). In contrast,
its binding affinity to murine CD22 (mCD22) was signifi-text of the structural data. Relative to the binding of Me-
-Neu5Ac, the BENZ compound was measured to have cantly weaker (rIP  5.0). In the absence of any experi-
mentally determined structural information for CD22,an rIP of 2.1, the NAP showed a significant increase,
with an rIP of 11, and the BIP gave a further slight im- sequence comparisons between SnD1 and the equiva-
lent regions of hCD22 and mCD22 were performed. Theprovement, with an rIP of 13. Since the Neu5Ac makes
conserved interactions with the protein in each case, N-terminal domains of mCD22 and hCD22 are 53.4%
identical. The corresponding values for Sn comparedthe differences in binding energy of these compounds
must arise from the differences in the interactions made with hCD22 and mCD22 are only 22% and 23.4%, re-
spectively. Nonetheless, residues important for stabiliz-by the substituents in the 9 direction. These extensions
consist of either one or two aromatic rings, and the ing the Ig fold are conserved between Sn and both
hCD22 and mCD22 as are the key residues contributinginteraction energy may therefore be expected to be pri-
marily hydrophobic in nature; however, the effect of to the Neu5Ac binding site [19]. Of the sequence differ-
ences between hCD22 and mCD22, only two are locatedbinding on any rotational degrees of freedom of the
aromatic rings must also be taken into account. The in or near the hydrophobic C-9 substituent binding site
(Figure 4).difference in apolar solvent-accessible surface buried
for the BENZ and NAP sialosides is 34 A˚2 , with a further In the current SnD1-sialoside complex structures, the
glycerol side chain of the sialoside principally interactsgain of 24 A˚2 for replacement of NAP with BIP. The
Structure
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Figure 4. Model of the BIP’s Interactions with CD22
(A) Amino acid sequence alignment of SnD1 with the N-terminal domains of human and murine CD22. Residues putatively involved in interacting
with the biphenyl rings are boxed in blue, while the Siglec hallmark arginine and tryptophans are boxed in red and green, respectively. The
secondary structure of SnD1 is displayed above the sequence alignments, with cysteines boxed in yellow. Species and accession numbers
are as follows: SnD1 (M. musculus), gi 4930109 (residues 1–119); mCD22 (M. musculus), gi 461664 (residues 4–122); hCD22 (H. sapiens), gi
105400 (residues 4–120).
(B) Structural model of the hCD22-BIP complex. The putative sandwiching of BIP’s biphenyl rings between residues Met109 and Arg111 is
depicted. The equivalent side chains in Snd1 (Leu107 and Val109) are drawn and labeled in purple.
with the main chain atoms of the protein, whereas the aromatic ring to the C-9 substituent (as in the NAP and
BIP sialosides) then led to a reduction in binding affinityhydrophobic extension beyond C-9 interacts predomi-
nantly with side chain atoms. A simple model-building to MAG. As discussed above for CD22, the structural
differences underlying these affinities are predicted toexercise for this region of hCD22 implies that the Val109
and Leu107 side chains of SnD1 would be substituted occur in the binding site for the C-9 substituent.
In the SnD1-BENZ complex structure, the side chainby an arginine (hCD22 Arg111) and a methionine (hCD22
Met109), respectively. From their predicted orientation of Tyr44 in the CC loop samples two alternative confor-
mations (Figure 5). One is the standard conformationand location, it appears plausible to propose that the
biphenyl substituent could be sandwiched between observed in the other Sn-sialoside complexes, and the
other somewhat increases the contact between the aro-these two side chains, hence contributing a substantial
binding affinity (Figure 4). Conversely, hCD22 Arg111 matic rings of the Tyr44 side chain and the benzoyl
substituent, although it fails to make the optimal ring-becomes Pro111 in mCD22, precluding this highly favor-
able packing mode. stacking interaction. This side chain rotation for Tyr44
is not observed in either of the SnD1-BIP or SnD1-NAPMAG
The benzoyl compound (BENZ) had a higher affinity than complex structures, as the extra aromatic ring of the
sialoside would sterically hinder any such conforma-Me--Neu5Ac to Sn (rIP  2.1), hCD22 (rIP  4.8), and
mCD22 (rIP  4.3) (Table 1). The affinity of BENZ for tional change. Sequence alignment of MAG with Sn indi-
cates a two-residue insertion in the CC loop of MAGMAG was, however, significantly greater, with an rIP of
790. Unlike for Sn and CD22, the addition of a second (Figure 5). The position of tyrosine residue Tyr46 in this
Design and Structure of Siglec-Inhibitor Complexes
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Figure 5. Model of BENZ’s Interaction with MAG
(A) Amino acid sequence alignment of SnD1 with the N-terminal domain of murine MAG. The aromatic residue putatively important in binding
BENZ is boxed in blue, while the Siglec hallmark arginine and tryptophans are boxed in red and green, respectively. The secondary structure
of SnD1 is displayed above the sequence alignments, with cysteines boxed in yellow. Species and accession numbers are as follows: SnD1
(M. musculus), gi 4930109 (residues 1–119); MAG (M. musculus), gi 6754614 (residues 2–120).
(B) Structural model of the MAG-BENZ complex. The higher affinity of BENZ to MAG could be due to the putative involvement of Tyr46 with
the sialoside’s phenyl ring, as observed in the BENZ-SnD1 complex. The equivalent side chain of Snd1 (Tyr44) is labeled and drawn in purple,
as in the NAP-SnD1 complex.
region of MAG may thus lie closer to the BENZ binding mammalian cell surfaces. The distribution of naturally
occurring sialic acid variants is species and cell-typesite and, hence, be capable of making an optimal inter-
action with the sialoside’s phenyl ring. Also by analogy specific; thus, these nine-carbon sugars are very appro-
priate mediators for selective cell-cell interactions. Thewith the situation for Tyr44 in the Sn-NAP and Sn-BIP
structures, the favorable interaction between Tyr46 and Siglecs form a family of structurally similar cell surface
glycoproteins that recognize distinct sialylated glycansthe C-9 substituent could be sterically precluded for the
longer NAP and BIP compounds. through an N-terminal Ig-like domain. The crystal struc-
ture of the N-terminal domain of the prototypic Siglec,
sialoadhesin (Sn), in complex with 2,3-sialyllactose re-Potential for Further Compound Design
vealed key features of the sialic acid binding site thatThe current Sn-sialoside structures indicate that the
sequence analysis predicted to be conserved through-substitution of the 9-hydroxyl group of Neu5Ac by an
out the family [19]. Conversely, surface regions immedi-amino group succeeds in maintaining a key hydrogen
ately abutting this site are expected to show some differ-bond between the ligand and the main chain carbonyl
ences between Siglecs. The original crystallographicof Leu106. Moreover, aromatic extensions at C-9 have
data thus provided the basis for a program of sialosidebeen shown to be capable of exploiting the hydrophobic
design aimed at developing compounds with enhancedbinding potential of an auxiliary site abutting the main
affinity and specificity to particular Siglecs. The crystalNeu5Ac binding site. Now that the efficacy of binding
structures of three such compounds (BENZ, NAP, andat the auxiliary site has been demonstrated and charac-
BIP) in complex with SnD1 are reported here. Theseterized, a second round of structure-based design should
results vindicate the original structure-based strategyallow improvement of sialoside binding to this site.
for the design of high-affinity inhibitors specific to indi-
vidual Siglecs. The structural analyses suggest explana-Biological Implications
tions for the observed affinity differences and provide
information on which to base further compound design.Sialic acids are common terminal monosaccharides in
carbohydrates attached to the proteins and lipids of Siglecs have been implicated in a diverse range of
Structure
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Table 3. Crystallographic Data
BEN-SnD1 NAP-SnD1 BIP-SnD1
Data Collection
Resolution range (A˚) (outer shell) 20–2.1 A˚ (2.17–2.1 A˚) 25–3 A˚ (3.11–3.0 A˚) 20–3.3 A˚ (3.42–3.3 A˚)
Completeness 99.9% (99.8%) 97% (72.5%) 89.7% (18.1%)
Total observations 116,504 29,346 12,504
Unique reflections 9,849 3,047 2,271
Average I/(I) (outer) 23.4 (2.2) 8.4 (2.1) 9.2 (1.8)
Rmerge (%) (outer) 11.0% (72.2%) 24% (50.6%) 19.2% (32%)
Refinement
Maximum resolution 2.1 3.0 3.3
Reflections (working set/test set) 9,155/512 2,721/136 1,959/195
Rwork/Rfree (%) 20.9/25.4 19.2/27.2 21.7/28.4
Number of atoms 013
Protein 928 928 914
Ligand 30 33 35
Water 71 — —
Ions 5 — —
Rmsd from standard stereochemistry
Bonds (A˚) 0.011 0.007 0.008
Angles () 1.3 1.2 1.4
Ramachandran plot
Most favored (%) 86 84 81
Additional (%) 14 16 18
Generous (%) 0 0 1
Disallowed (%) 0 0 0
Rmsd from SIA-SnD1 structure
All atoms (A˚) 0.9 0.7 0.7
C atoms (A˚) 0.4 0.5 0.4
Values in parenthesis correspond to the highest resolution shells.
Rmerge  	|Ihkl  
Ihkl|/	Ihkl.
Rwork  	hkl||Fo|  |Fc||/	hkl| Fo| for all data, except for the subset that was used for the Rfree calculation.
SIA structure is the protein taken from chain A of the SnD1-2,3-sialyllactose complex (Protein Data Bank accession code 1QFO). Rmsd, root-
mean-square deviation.
Experimental Proceduresbiological functions involving cell surface recognition
events. MAG (myelin-associated glycoprotein) is puta-
Production of the Recombinant N-Terminal Domaintively involved in glial cell-neuron interactions, influenc-
of Sialoadhesin
ing myelination, axonal growth regulation, and signal A soluble functional fragment of murine sialoadhesin (SnD1; resi-
transduction [36, 37]. CD22 is found exclusively on B dues 1–118) was expressed and purified from Chinese hamster
ovary (CHO) cells as previously described [39]. Briefly, a stably ex-cells and has been shown to regulate B cell activation
pressed clone of SnD1 in plasmid pEE14 secreted at levels up tothresholds through cis interactions with the B cell recep-
10 mg/l of medium. SnD1 was purified from the supernatant with ator complex and to promote homing of B cells to the
3D6 mAb Sepharose 4B affinity column. Immediately prior to crystal-bone marrow via trans interactions with endothelial cell
lization the SnD1 was concentrated to 5 mg/ml in the presence of
ligands [28]. Sn, expressed on tissue macrophages, has 10 mM DTT and further purified on a Superdex 75 HR 10/30 column
no phagocytic activity per se but could influence, either (Pharmacia). SnD1 elutes from the gel filtration column in two peaks
that contain nonphysiological dimers (arising from exposure ofpositively or negatively, various macrophage effector
Cys17 in the SnD1 construct) and monomers (used for the crystalli-functions [38]. It also shows preferential binding to my-
zation trials), respectively. The inclusion of the reducing agent DTTeloid cells compared with other hematopoietic cells, sug-
prior to the gel filtration was a departure from the established proto-gesting involvement in the interaction of macrophages
col but was valuable, as it diminished the proportion of dimerized
and myeloid cells. However, many questions remain re- SnD1.
garding the role of sialylated glycan recognition in the
mechanism of action and, indeed, the functions in gen-
Hapten Inhibition Assays
eral of MAG, CD22, and Sn as well as the other Siglecs. Fc chimeras containing the three N-terminal domains of human
Sialosides with high affinity for specific Siglecs may CD22 (hCD22d1-3-Fc) [40], murine CD22 (mCD22d1-3-Fc), or murine Sn
(Snd1-3-Fc) were produced in COS cells as described [14]. Purifiedimmediately be exploited to help address these ques-
Fc chimeras were labeled with carrier-free Na125I (Amersham,tions. Indeed, the BIP sialoside has been used to dissect
Braunschweig, Germany) and complexed with equimolar concentra-out the role of sialic acid binding in CD22 function [28].
tions of anti-human IgG (Biodesign, Kennebunk, ME) to be used inThus, the development of the current generation of si-
binding assays with glutardialdehyde-fixed murine myeloma cells
alosides already exemplifies the potential for aiding func- AG8 or human erythrocytes as described [14]. For inhibition assays
tional studies by yoking together structural and chemical 10 l radio-iodinated Fc chimeras were mixed with an equal volume
of the sialoside (pH 7.5) and incubated for one hour at 4C beforebiology.
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10 l cells were added. After an overnight incubation at 4C, the resolution BIP-SnD1 structure. For the high-resolution BENZ-SnD1,
waters and a sulfate molecule were finally added to the model. Ancells were washed and the bound radioactivity was quantified. The
50% inhibition concentrations (IC50) and the relative inhibitory poten- alternate conformation for the side chain of Tyr44 was also con-
firmed by inspection of Fo  Fc maps, and, on the basis of a seriescies (rIP) were calculated as described [25].
of trial runs with varying ratios in CNS, an occupancy of 50% was
allocated to each conformation.Crystallization of SnD1-Inhibitor Complexes
Stock solutions of the inhibitors were prepared in deionized water
at 1.25 M concentration (except for BIP, which was dissolved to Structural Analysis
1.25 M concentration in 30% (w/v) PEG 4000, 0.1 M sodium citrate The quality of the final models was assessed with PROCHECK [48].
[pH 5.6], and 0.2 M ammonium acetate). Inhibitor concentrations of Solvent accessibilities were calculated with NACCESS [49], and
2.5 mM (BIP) or 25 mM (BENZ and NAP) were added to a solution surface characteristics were analyzed with GRID [50]. The difference
of SnD1 concentrated to 10 mg/ml in 10 mM HEPES (pH 7.5) with in binding energies (G) between two compounds was estimated
10 mM DTT. Crystallization conditions were screened at 17C by from their rIPs for the protein with respect to a reference compound.
the sitting drop method [41], and the subset of solutions from the G  1.368 log(rIPcompound1/rIPcompound2). Structural superpositions
Hampton screens [42, 43] with PEG 4000 concentrations between were performed with SHP [51], and structural figures were produced
20% and 30% (a selection based on previously successful SnD1 with BOBSCRIPT [52], RASTER3D [53], and GRASP [54].
cocrystallization conditions [39]). Typically drops contained 1 l of
SnD1-inhibitor solution plus 1 l of reservoir solution. Small needle-
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Accession Numbers
Crystallographic coordinates have been deposited in the Protein
Data Bank under accession codes 1od9 (BENZ-SnD1), 1od7 (NAP-
SnD1), and 1oda (BIP-SnD1).
